Skip to main content

What the FDA labels say about taking them together

Atazanavir and saxagliptin

Saxagliptin's FDA label of January 27, 2026 names atazanavir in its drug interactions section; the atazanavir labels PlainMeds reads (2) do not name saxagliptin. The saxagliptin label: “Similar significant increases in plasma concentrations of saxagliptin are anticipated with other strong CYP3A4/5 inhibitors.”

Check it at the source: the atazanavir FDA label on DailyMed (effective August 6, 2025, Aurobindo Pharma Limited); the saxagliptin FDA label on DailyMed (effective January 27, 2026, Glenmark Pharmaceuticals Inc., USA).

What does the atazanavir label say about saxagliptin?

Atazanavir's label (effective August 6, 2025) and its 1 other brand-application label do not name saxagliptin in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Atazanavir Sulfate), Aurobindo Pharma Limited, effective August 6, 2025 (SPL set 7fbea274-d6b5-4faa-bbf0-05fefab42114), via openFDA; the full label on DailyMed

What does the saxagliptin label say about atazanavir?

Saxagliptin label, drug interactions

Similar significant increases in plasma concentrations of saxagliptin are anticipated with other strong CYP3A4/5 inhibitors (e.g., atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin).

Source: FDA drug label (SAXAGLIPTIN), Glenmark Pharmaceuticals Inc., USA, effective January 27, 2026 (SPL set e286ffd4-c598-47fb-af06-2e15f7e6f99f), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

4Atazanavir generic labelers
3Saxagliptin generic labelers
AtazanavirSaxagliptin
Labeled forHIVType 2 diabetes
Boxed warningNoNo
Pharmacy cost (NADAC)$2.23 per capsule 300 mg capsule$1.04 per tablet 5 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?